Arthritis Clinical Trials in Birmingham

View 29 new treatments for Arthritis in Birmingham, AL. Every day, Power helps hundreds of Arthritis patients connect with leading medical research.
View 34 trials in Birmingham
Filter (34)

COVID-19 VaccinE Response in Rheumatology Patients

Research Clinic, Hoover + 3 more

This trial tests an extra dose of the COVID-19 vaccine in patients with autoimmune diseases. It aims to see if pausing their medications temporarily can make the vaccine more effective. The goal is to improve their immune response to COVID-19.Show More
Recruiting

No Placebo Trial

Phase 4
Est. 5 - 8 Weeks
Jeffrey R Curtis, MD MS MPH
Principal Investigator

COVID-19 Vaccines for Rheumatic Diseases

Research Clinic, Northport + 1 more

Based on the experience with influenza, pneumococcal, and shingles vaccinations in rheumatic disease populations, it is clear that some disease modifying anti-rheumatic drugs and the immunomodulatory therapies used to treat immune-mediated inflammatory diseases have the capacity to blunt immune responses to COVID-19 vaccines. Several studies have suggested that patients with autoimmune conditions may be at increased risk of poor COVID-19 outcomes. There is an urgent need to better clarify the immunogenicity and safety of COVID-19 vaccines in people living with rheumatic disease who use immunomodulatory therapies. Boosters at annual or other frequency are available, and there is a need to understand whether these vaccines can be given concurrently with other routine vaccines.Show More
Waitlist

No Placebo Trial

Phase 4
Est. 6 - 12 Weeks
Unregistered Study Lead
Research Team

TG-C for Knee Osteoarthritis

Kolon TissueGene Clinic, Birmingham + 1 more

This trial tests TG-C, an injection into the knee, for people with moderate to severe knee osteoarthritis. It aims to see if TG-C can reduce pain and improve knee function by potentially altering the disease. The study will monitor patients for safety and effectiveness over time. TG-C has been previously studied for its potential to improve knee joint function and reduce pain in osteoarthritis patients.Show More
Waitlist
Phase 3
Est. 3 - 6 Weeks
David W Romness, MD
Principal Investigator

Non-Surgical Interventions for Knee Osteoarthritis

Research Clinic, Birmingham + 1 more

There is an urgent public health need to reduce reliance on opioids for effective long-term pain management, particularly in knee osteoarthritis (KOA). This effectiveness trial will compare commonly recommended treatments to reduce pain and functional limitations in KOA.These results will lead to improved patient selection for treatment and inform evidence based guidelines by offering well-tested, effective, non-surgical alternatives.Show More
Waitlist

No Placebo Trial

Phase 3
Est. 4 - 6 Weeks
Steven Cohen, MD
Principal Investigator

Amniotic Suspension Allograft for Knee Osteoarthritis

Organogenesis Clinic, Birmingham + 2 more

This trial is testing if injecting ASA into the knee can help people with knee osteoarthritis feel better. The study will check pain levels, knee function, and safety over several months. ASA (Amniotic Suspension Allograft) has been shown to be an effective treatment for knee osteoarthritis in previous studies.Show More
Recruiting
Phase 3
Est. 3 - 12 Weeks
Unregistered Study Lead
Research Team

Non-TNFi Biologics vs Targeted Synthetic DMARDs for Rheumatoid Arthritis

Research Clinic, Birmingham + 2 more

This trial is testing advanced medications for RA patients who haven't responded to standard treatments. It compares biologic drugs that target immune proteins and synthetic drugs that block harmful molecules in immune cells. The goal is to see which treatment improves patients' quality of life and daily functioning better. Biologic therapies have notably improved the treatment of RA, making disease remission a realistic goal.Show More
Recruiting

No Placebo Trial

Phase 3
Est. 3 - 6 Weeks
Jasvinder Singh, MD
Principal Investigator

Health Coaching + Incentives for Knee Osteoarthritis

Research Clinic, Birmingham + 1 more

The aims are to determine whether 1) an incentive based on behaviorally-enhanced gamification and social incentives and 2) health coaching can promote adherence to exercise and physical activity after physical therapy for osteoarthritis of the knee (KOA). The research design is a randomized clinical trial with factorial design This randomized clinical trial of 254 patients using a factorial design will leverage a clinical trial platform developed through the University of Pennsylvania that allows for the remotely capture important patient-reported outcomes and other interaction through a participant's smart phone. The investigators will randomize participants to receive social incentives with gamification to promote adherence to prescribed exercises as well as maintenance of greater levels of physical activity and compare to controls that receive a Fitbit but no additional incentive. Participants may also be randomized to receive a health coach. The investigators will utilize mobile applications for smart phones and wearable activity trackers through the Way-to-Health platform and assess, in real time, the impact of the interventions on patient-reported function and pain (as measured by the Knee Osteoarthritis Outcome Score) as well as physical activity. Participants will be followed for 2 years, with a total of 5 in-person visits. Knee osteoarthritis (KOA) is one of the most prevalent and disabling conditions among Veterans and accounts for high morbidity and high costs for the VA. Importantly, while physical therapy is valuable for patients with KOA, lack of adherence to home exercises and low overall physical activity limit the durability of response. The current proposal aims to address two important knowledge gaps in the management of KOA in order to improve pain and function.Show More
Waitlist

No Placebo Trial

Phase 3
Est. 3 - 12 Weeks
Joshua F. Baker, MD MSCE
Principal Investigator

Guselkumab for Psoriatic Arthritis

Janssen Clinic, Birmingham + 1 more

The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.Show More
Recruiting
Phase 3
Est. 6 - 12 Weeks
Janssen Research & Development, LLC Clinical Trial
Study Director

Ustekinumab/Guselkumab for Juvenile Psoriatic Arthritis

Janssen Clinic, Birmingham + 1 more

The purpose of this study is to evaluate the pharmacokinetics (PK), efficacy, safety and immunogenicity of ustekinumab and guselkumab in active juvenile psoriatic arthritis (jPsA).Show More
Recruiting

No Placebo Trial

Phase 3
Est. 3 - 12 Weeks
Janssen Research & Development, LLC Clinical Trial
Study Director

Abatacept Injection for Juvenile Idiopathic Arthritis

Research Clinic, Birmingham + 1 more

This is a research study to test whether a once-weekly injection of abatacept will prevent the progression of Juvenile Idiopathic Arthritis (JIA) to a more severe form. To evaluate the effectiveness of a 24-week course of treatment with abatacept plus usual care versus usual care to prevent polyarthritis (≥5 joints), uveitis, or treatment with other systemic medication within 18 months of randomization in children with recent-onset limited JIA.Show More
Waitlist

No Placebo Trial

Phase 3
Est. 6 - 12 Weeks
Stephen Balevic, MD
Principal Investigator
Page 1 of 4

Frequently Asked Questions

How much do arthritis clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range. Further, most trials will cover the costs of an Uber to-and-from the clinic. Factors that can affect compensation include the phase of the trial, the length of the trial, the frequency of visits, and the specific condition being studied.

Do I need to be insured to participate in a medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on Cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

How do arthritis clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll typical be sorted into one of the treatment groups, and will receive your study drug. For some trials, there is a chance you'll receive a placebo. Across arthritis trials in Birmingham, 42% of clinical trials have a placebo. Typically you'll be required to check-in with the clinic every month or two. The average trial length in this city for arthritis patients is 6 Months.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in getting approval for a specific condition. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. Phase 2 trials are those where the drug has some data showing safety in humans, but where effectiveness has typically only been shown in animals and non-human experiments. Phase 1 trials are the trials where we don't have safety data in humans. As a general rule, phase 3 trials are more promising than phase 2, and phase 2 trials are more promising than phase 1.

Where in Birmingham is research being conducted for arthritis?

The University of Alabama at Birmingham is a prominent hospital conducting arthritis clinical trials, with approximately 11 trials as of 2024. Additionally, trials are taking place in the central area of Birmingham.

What promising new drugs are being tested?

In Birmingham, arthritis research is focusing on treatments like Monoclonal Antibodies and Immunomodulatory Therapies. Notable drugs being studied include Guselkumab, Ustekinumab, and Baricitinib.